Find NervGen Pharma Smart Score, expert sentiment, charts & stats. CI. 2022, compared to $1. - May 15, 2023) - NervGen Pharma Corp. The current price NervGen Pharma ( NGENF) is trading at is $1. May 12, 2022 – NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. Receives Up to $1. Stock After deciding where to buy NervGen Pharma Corp. 40, and during the day (based on 14 day Average True Range), to. Nervgen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF). operates as a regenerative medicine company engaged in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. 12% All time 3. Vancouver, Canada. The 1-8 reverse split was announced on Friday, April 28th 2017. 5 million from the exercise of stock options and common share purchase warrants. This step is necessary to understand whether this company fits your financial goals and strategy. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, will present at the H. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system. It is currently in Phase 1 FDA trials in humans and is about to go into Phase 2. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date. NervGen Pharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, will present at the H. Vancouver, British Columbia--(Newsfile Corp. (the “Company” or “NervGen”) is a publicly traded company incorporated on January 19, 2017, under the Business Corporations Act (British Columbia). 12,500. CI. View real-time stock prices and stock quotes for a full financial overview. 11%) At close: 02:05PM EST 1d 5d 1m 6m YTD 1y 5y Max NervGen Pharma's stock was trading at $1. - November 12, 2021) - NervGen Pharma Corp. 50 per unit, for aggregate gross proceeds of. Vancouver, British Columbia--(Newsfile Corp. NOT FOR DISTRIBUTION TO U. Phase 1 clinical trial dosing completed Phase 1b/2a clinical trial of NVG-291 in individuals with chronic and subacute spinal cord injuries expected to commence in Q3 2023 Cash and investments of $18. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to […] During the 2022 fiscal year and 2023 to date, we have received proceeds of approximately CA$3. Financial Highlights. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. Current Price 1. The Company's initial target indication is spinal cord injury. Vancouver, British Columbia-- (Newsfile Corp. Kelly currently serves on the Board of Directors of ARS Pharmaceuticals, which he joined in May 2019. The options have been granted in accordance with the policies of the. He was a founder and the CEO of Response Biomedical Corp. Get the latest NervGen Pharma Corp (NGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 6 million. - October 23, 2023) - NervGen Pharma Corp. 1m. All options. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system. is followed by the analysts listed above. 10% least volatile stocks in CA Market. May 12, 2022 – NervGen Pharma Corp. Barchart. 04%. For example, although. Opens the Market (CNW Group/TMX Group Limited) Industrial Alliance Securities analyst Chelsea Stellick has launched coverage of NervGen Pharma (NervGen Pharma Stock Quote. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. 8 million as of September 30, 2023, compared to $22. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. +0. Currently, those suffering from a spinal cord injury. Vancouver, British Columbia–(Newsfile Corp. NervGen Pharma Corp (NGENF) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Fair Ratio; Current PB Ratio: 15. Vancouver, British Columbia--(Newsfile Corp. - October 27, 2021) - NervGen Pharma Corp. CI. 5 million as of December 31, 2022. NervGen Pharma Corp. NervGen Pharma To Receive More Than US$3 Million From Wings For Life To Support Upcoming Clinical Study In Spinal Cord Injury. 25 average) Interesting medical treatments currently in trials Long term play Nice long ~2 year consolidation is in progress, recent reject from the top side of wedge will present entry. C. Announces Executive Changes 2022: CI NervGen Pharma Corp. - June 20, 2023) - NervGen Pharma Corp. yahoo. is followed by the analysts listed above. (TSX-V: NGEN;. View real-time stock prices and stock quotes for a full financial overview. The stock could jump quickly if the Company receives EU. 0 million. 52%) At close: 03:59PM EST 1d 5d 1m 6m YTD 1y 5y Max Full. Jerry Silver, inventor of NervGen's. NervGen Pharma to Receive More Than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury. Equity proceeds of CA$22M+ raised during 2022 fiscal year; Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoingNervGen Pharma Corp. View the latest NervGen Pharma Corp. Analyst Forecast According to 8 analysts, the average rating for AMAM stock is "Buy. Loss and comprehensive loss - - - (4,967,595). 13. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " or the " Company "), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public. 81(+0. Nervgen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. 3 million in proceeds from the exercise of options and warrants during. Food and Drug Administration (FDA) has. Investor. 0 million. Oct. The company’s lead target. 13 per share for a period of 10 years. 1. Get a free in-depth analysis of NervGen Pharma (TSE:NGEN) stock. 0 million as of March 31, 2023, compared to $22. The Company's initial target indication is spinal cord injury. C. May 20, 2021 – NervGen Pharma Corp. Dr Silver’s innovation offers renewed hope for the estimated 300,000 to 500,00 North Americans who dream of one-day regaining sensation and motor function in their paralysed limbs. 75. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury. 2vPAiWb0mXkOBCwglAvhchTz-DWl2Ho1ue7QAsXT. Canada - NervGen Pharma Corp. ISIN. Jerry Silver, inventor of. 35 (1. NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. All three major U. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later. 059 expected by the market. (TSXV: NGEN) (OTCQX: NGENF), a clinical. Jerry Silver, inventor of. 1 million in proceeds from the exercise of. 39. NervGen had cash and investments of $16. Firm Analyst Encode Ideas, LP Hogan Mullally Paradigm Capital Scott McAuley, PhD NervGen Pharma Corp. +0. NervGen Pharma Grants Stock Options Newsfile - Tue May 23, 3:41PM CDT . 5 million as of December 31, 2022. C. Track NervGen Pharma Corp (NGENF) Stock Price, Quote, latest community messages, chart, news and other stock related information. 0 million as of March 31, 2023. Analysts publish ratings. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 376,000 incentive stock options to. Daniel Mikol, will present at the 2023 International Spinal. Vancouver, British Columbia--(Newsfile Corp. Department of Defense and PFP Biosciences are the most recent investors. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has closed its previously announced non. The stock just got a big boost from new clinical results, and that bodes well for fans of NervGen Pharma (NervGen Pharma Stock Quote, Charts, News, Analysts, Financials TSXV:NGEN), according to iA. Projected one-year return to target: 168 per cent. (TSX-V: NGEN; OTCQX: NGENF) ( NervGen or the Company ), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that its Chief Medical Officer, Dr. (the “Company” or “NervGen”) is a publicly traded company incorporated on January 19, 2017, under the Business Corporations Act (British Columbia). (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its financial. com. Vancouver, Canada--(Newsfile Corp. NervGen Pharma's estimated fair value is CA$3. Vancouver, Canada. NervGen's lead drug candidate, NVG-291, is currently planned to be evaluated in a Phase 1b/2a clinical trial. According to present data NervGen Pharma's NGEN shares and potentially its market environment. Corporate Communications (604) 537-2094. - June 2, 2023) - NervGen Pharma Corp. Financial Highlights. Vancouver, Canada. The best long-term & short-term NervGen Pharma share price prognosis. July 14, 2022— NervGen Pharma Corp. C. NervGen Pharma Corp. April 6, 2022 – NervGen Pharma Corp. Vancouver, Canada. Nancy ThompsonOffice (212) 532-2208Mobile (917) 371-4053Just because a business does not make any money, does not mean that the stock will go down. 3 Bil: BMRN Biomarin Pharmaceutical Inc: Jdmlf: $15. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later. 00. (TSX-V: NGEN) (OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date of certain stock options granted to a consultant of the. The decrease was primarily due to non-cash stock-based compensation expense related to option grants to employees and consultants, and the timing of the related vesting, partially offset by increases in legal, professional, and. Vancouver, British Columbia--(Newsfile Corp. 87 -0. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2021. +1. NervGen is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. forecasts only using an unbiased methodology and our. Stocks. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, will present at the H. 2021 ANNUAL FINANCIAL STATEMENTS 5 1. 34 0. Read More ». operates as a regenerative medicine. 2017. February 28, 2022 – NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock. Market Average Movement. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing. , (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided a positive update on its Phase 1 program with NVG-291 in healthy volunteers at the 14th Annual Meeting of. About NervGen . NervGen Pharma Corp. The net cash burn for Q2 2023 from operating activities was approximately $2. 30/share on May 31, but not quite reaching the high. Today ||| 52-Week Range. Nov. NervGen Pharma has a market capitalisation of CA$114m and burnt through CA$17m last year, which is 15% of the company's market value. This is similarly the case for more than a million Americans who have debilitating peripheral nerve injuries. Newsfile Corp. The net cash burn for Q3 2023 from operating. – May 31, 2022) – NervGen Pharma Corp. 48 +11. June 3, 2020 – NervGen Pharma Corp. With a revolutionary drug that could reverse the damage caused by Alzheimer’s disease, the company is certainly growing and has some ambitious plans. 6209 Nancy Thompson, Vorticom Public Relations [email protected]. The name was changed to NervGen Pharma Corp. Ruffolo exercisable at a price of $1. NervGen Pharma Corp. Trending Stocks Technical Analysis Screener Penny Stock Screener Daily Analyst Ratings Daily Insider Trading Tracker. ,. NOT FOR DISTRIBUTION TO U. ,. 3%. 1 million as of June 30, 2023, compared to $22. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Alnylam Pharmaceuticals Inc: Kkvsytx: $20. 55 per unit for gross proceeds of. 30(-0. NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023. NervGen Pharma Corp. Vancouver, British Columbia-- (Newsfile Corp. Vancouver, Canada October 18, 2021 – NervGen Pharma Corp. According to present data NervGen Pharma's NGEN shares and potentially its market environment have been in bearish cycle last 12 months (if exists). 5 million from the exercise of stock options and common share purchase warrants. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial results for the third quarter ended September 30, 2022 and provided an operational update. Currency in USD Follow 1. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions. NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Discover NervGen Pharma's earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. Stock-based compensation - - 797,101 - 797,101 . NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. Get a free in-depth analysis of NervGen Pharma (TSE:NGEN) stock. announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to. Huitt Tracey, Corporate Communications htracey@nervgen. As of Nov 01. – May 31, 2022) – NervGen Pharma Corp. 14. , (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided an update on its Phase 1 program with NVG-291 at the Society for Neuroscience’s Neuroscience. +1. is a clinical-stage biotech company. The company’s lead target. under the Business Corporations Act (British Columbia). (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its financial. 77% 5 years 11. | 1,176 followers on LinkedIn. For instance, just consider the fact that Wall Street analysts are now estimating peak annual sales for Biogen’s new drug will range from $10 billion to $50 billion. NervGen Pharma press release (OTCQX:NGENF): Q3 GAAP EPS of -$0. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of John Ruffolo. Since then, NGENF stock has increased by 19. 68NervGen Pharma Completes Dosing in its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results. Vancouver, British Columbia--(Newsfile Corp. Cash and Investments: NervGen had cash and investments of $14. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. 10% most volatile stocks in CA Market. 1 million in proceeds from the exercise of options and. 75 per share for a period of five years and that vest equally every three months over a one-year period. Vancouver, Canada. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. 5 million as of December 31, 2022. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic disease in which the immune system attacks myelin (the fatty coating around neurons) in the brain and spinal cord, damaging the neurons and impairing signal transmission. Since then, NGENF stock has increased by 19. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. After the height of the COVID-19. +0. The net cash burn for Q1 2023. 2 based on 2 Stage Free Cash Flow to Equity. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical. NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury. NervGen Pharma Corp. 620 CAD 7 Days Forecast Get It Now! 1-Year Forecast * 1. Huitt Tracey. Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repair Lukashev brings over 20 years’ experience including work at Biogen and the ALS Therapy Development Institute Vancouver, Canada. Currency in CAD Follow 1. February 14, 2023 […] Cash and Investments: NervGen had cash and investments of $14. November 18, 2019 – NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal. It does not constitute a recommendation to buy or sell any stock, and. 5 million for the same period in 2021. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. Vancouver, British Columbia-- (Newsfile Corp. S. View daily, weekly or monthly format back to when NervGen Pharma Corp. June 27, 2023. Browse analyst ratings and price targets on all stocks. Michael Kelly to the position of President &CEO effective April 10, 2023. S. +3. NervGen Pharma Corp. Top Analyst Stocks. July 27, 2020 — NervGen Pharma Corp. NervGen Pharma Corp. - April 10, 2023) - NervGen Pharma Corp. . The $1. S. Mr. Bill Radvak is a co-founder and has been the Executive Chairman or Chairman of NervGen since its inception. All options, which will vest over two years, have been granted in accordance with the policies of the TSX Venture Exchange and the Company’s. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for. NervGen plans to initiate. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 Nov. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the first quarter ended March 31, 2023. 39 to $1. Dr Silver’s innovation offers renewed hope for the estimated 300,000 to 500,00 North Americans who dream of one-day regaining sensation and motor function in their paralysed limbs. 3915 +0. 88% from a day low at $1. Paul Brennan to. June 27, 2023 – NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. 005 USD for 2028 November 11, Saturday with technical analysis. The corporate office of the Company is located atVancouver, Canada. 0 Bil: INCYView live NervGen Pharma Corp. 87%. Get NervGen Pharma Corp (NGEN. Latest Financial Results Quarter Ended September 30, 2023 Financial Statements MD&A Past Financial Results 2023 Quarter Ended June 30, 2023 Financial Statements MD&A Quarter Ended March 31, 2023 Financial Statements MD&A 2022 Year Ended December 31, 2022 Quarter Ended September 30, 2022 Quarter Ended June 30,. Vancouver, Canada August 2, 2022 – NervGen Pharma Corp. NervGen's lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. (TSX-V: NGEN) (OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be giving an oral presentation at the upcoming American Spinal Injury Association (ASIA) 50th Annual Scientific Meeting being held on April 17-19, 2023. - June 27, 2023) - NervGen Pharma Corp. . Stock-based compensation 4,015,673 3,415,360 Unrealized foreign exchange (31,377) 16,610 Changes in non-cash working capital: Accounts receivable (1,408) 59,908. The following discussion is management's assessment and analysis of the results of operations and financial conditions of NervGen Pharma Corp. 0164. Vancouver, Canada. 7200. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291 Oct 27 NervGen Pharma Corp. Today’s Change. Mr. NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. NervGen Pharma Corp. -1. The following discussion is management's assessment and analysis of the results of operations and financial conditions of NervGen Pharma Corp. 05 today. The stock market is getting a jolt from the inflation report. Vancouver, British Columbia-- (Newsfile Corp. stock news by MarketWatch. 7200. These lofty numbers are. ’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions. 02 1. forecasts only using an unbiased methodology and our. Vancouver, British Columbia--(Newsfile Corp. nancyt@vorticom. NervGen's lead drug candidate, NVG-291, is currently planned to be evaluated in a Phase 1b/2a clinical trial. As of 2023 November 11, Saturday current price of NGENF stock is 1. stock news by MarketWatch. 10. Daniel Mikol, will present at the 2023 International Spinal Research Trust Network Meeting being held September 14-16 in London, UK. (TSX-V: NGEN;. Vancouver, British Columbia--(Newsfile Corp. Today ||| 52-Week Range. August 19, 2021 – NervGen Pharma Corp. Its lead product candidate is the NVG-291 that is in clinical studies for the. finance. S. 36. NervGen Pharma Corp. is a clinical-stage biotech company. 5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury NervGen Pharma Corp. NervGen's lead drug candidate, NVG-291, is currently planned for a Phase 1b/2a clinical trial. (NGENF) stock discussion in Yahoo Finance's forum. See the latest NervGen Pharma Corp Ordinary Shares stock price (XTSX:NGEN), related news, valuation, dividends and more to help you make your investing decisions.